Roche Diagnostics R&d investments in 2024 across the roche diagnostics division. the roche partnering process can be encapsulated in four steps. at each step we can modify and tailor the relationship to the specific needs of each potential partner and depending on what is best for the asset. Roche is handing over $595 million to bolster its foundation medicine business with a deal to snap up saga diagnostics. through the deal, the swiss major gets it hands on saga’s pathlight, a.
Roche Diagnostics On apr. 15, 2026, foundation medicine, an independent affiliate of the roche group, announced it is set to expand its monitoring portfolio with saga diagnostics’ tumor informed molecular residual disease (mrd) platform as a result of roche entering into a definitive merger agreement to acquire saga. roche will pay a total of up to $595 million, inclusive of commercial and regulatory. Roche has entered into a definitive merger agreement to acquire saga diagnostics for up to $595 million, bringing the pathlight tumor informed molecular residual disease platform to foundation medicine. pathlight uses a proprietary combination of whole genome sequencing and digital pcr to identify structural variants, enabling ultra sensitive detection of minimal residual disease in cancer. Roche acquires saga diagnostics for up to $595 million the deal will integrate saga's pathlight mrd platform into roche's affiliate foundation medicine. Roche subsidiary, foundation medicine, touts the mrd testing space as “one of the fastest growing areas within diagnostics”.
Roche Partnering With Diagnostics Roche acquires saga diagnostics for up to $595 million the deal will integrate saga's pathlight mrd platform into roche's affiliate foundation medicine. Roche subsidiary, foundation medicine, touts the mrd testing space as “one of the fastest growing areas within diagnostics”. Sciety portfolio company saga diagnostics has entered into an agreement to be acquired by foundation medicine, inc., a global precision medicine company and an independent subsidiary of roche, for a deal value of up to usd 595 million, including commercial and regulatory milestone payments. saga diagnostics is a biotechnology company developing advanced diagnostic methods to detect and monitor. Roche has agreed to acquire saga diagnostics for $595 million, further strengthening its molecular residual disease (mrd) testing capabilities. saga’s pathlight platform, introduced in 2025. Press release. sciety portfolio company saga diagnostics has entered into an agreement to be acquired by foundation medicine, inc., a global precision medicine company and an independent subsidiary of roche, for a deal value of up to usd 595 million, including commercial and regulatory milestone payments. To discover and develop degrader antibody conjugates (dacs) targeting key cancer pathways. read the full story. we are passionate about advancing science – no matter where it comes from. we identify the best innovations, whether internal or external, and delivering them to patients.
Comments are closed.